Waldenstrom's Macroglobulinemia
Links shared publicly online about this topic
Bing Center for Waldenstrom's Macroglobulinemia
wmprogram.org — “The Waldenstrom's Macroglobulinemia program at the Dana-Farber Cancer Institute, a Harvard Medical School affiliate, has spearheaded national and international efforts to bring basic and clinical studies to WM (recently defined as IgM secreting lymphoplasmacytic lymphoma). Our site provides information about this disease, our program, our clinic, our clinical trials and basic research efforts, and current news for both patients and physicians.” View full resource at wmprogram.org
Most Recently Shared on January 30, 2010 at 3:22 pm By:
Waldenstrom's Clinical Trials info: http://bit.ly/ajTnDC
Oncology Medical News about Waldenstrom Macroglobulinemia
mdlinx.com — “microRNA-dependent modulation of histone acetylationin Waldenstrom macroglobulinemia” View full resource at mdlinx.com
Most Recently Shared on June 23, 2010 at 4:36 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
microRNA-dependent modulation of histone acetylationin Waldenstrom macroglobulinemia: Blood http://bit.ly/9Z85aC #oncology
Oncology News & Articles - MDLinx - Waldenstrom Macroglobulinemia on #MDlinx
mdlinx.com — “Oncology News & Articles - MDLinx - Waldenstrom Macroglobulinemia on #MDlinx” View full resource at mdlinx.com
Most Recently Shared on August 10, 2010 at 11:38 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström ... http://bit.ly/d7TZI0 #oncology
Researchers Identify Genetic Mutation Responsible For Most Cases Of Waldenstrom's Macroglobulinemia
medicalnewstoday.com — “Scientists at Dana-Farber Cancer Institute have identified a gene mutation that underlies the vast majority of cases of Waldenstrom's macroglobulinemia, a rare form of lymphoma that has eluded all” View full resource at medicalnewstoday.com
Most Recently Shared on December 13, 2011 at 10:05 am By:
Researchers Identify Genetic Mutation Responsible For Most Cases Of Waldenstrom's Macroglobulinemia http://t.co/hoH9WkT0 #genetics
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results Of Perifosine As A Single Agent For The Treatment Of Waldenstrom's Macroglobulinemia
medicalnewstoday.com — “Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the Company) announced that an article entitled Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine” View full resource at medicalnewstoday.com
Most Recently Shared on January 30, 2010 at 2:06 pm By:
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results Of Perifosine As A Single Agent For The Treatment Of... http://mnt.to/3wZx
Nice review of the role of the bone marrow microenvironment in #Waldenstrom's macroglobulinemia : http://t.co/LZaRP57w.
t.co — “Nice review of the role of the bone marrow microenvironment in #Waldenstrom's macroglobulinemia : http://t.co/LZaRP57w.” View full resource at t.co
Most Recently Shared on November 13, 2011 at 2:02 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Nice review of the role of the bone marrow microenvironment in #Waldenstrom's macroglobulinemia : http://t.co/LZaRP57w.
Ongoing study at M. D. Anderson for relapsed #Waldenstrom macroglobulinemia with oral pomalidomide: http://t.co/fNkf9VTX.
t.co — “Ongoing study at M. D. Anderson for relapsed #Waldenstrom macroglobulinemia with oral pomalidomide: http://t.co/fNkf9VTX.” View full resource at t.co
Most Recently Shared on March 18, 2012 at 12:50 am By:
Robert Z. Orlowski Physician, Doctor, and Internist
Ongoing study at M. D. Anderson for relapsed #Waldenstrom macroglobulinemia with oral pomalidomide: http://t.co/fNkf9VTX.
Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia - Full Text View - ClinicalTrials.gov
clinicaltrials.gov — “Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia - Full Text View - ClinicalTrials.gov” View full resource at clinicaltrials.gov
Most Recently Shared on February 15, 2010 at 4:49 pm By:
Potential breakthrough trial for Waldenstrom's. Double stem cell transplant, 50-90 days apart. http://bit.ly/d1LzKb
Hyperviscosity Syndrome: eMedicine Emergency Medicine
emedicine.medscape.com — “Overview: Hyperviscosity syndrome (HVS) refers to the clinical sequelae of increased blood viscosity. Increased serum viscosity usually results from increased circulating serum immunoglobulins and can be seen in such diseases as Waldenstrom macroglobulinemia and multiple myeloma. It ...” View full resource at emedicine.medscape.com
Most Recently Shared on April 27, 2010 at 4:11 am By:
Hyperviscosity syndrome (HVS) refers to the clinical sequelae of increased blood viscosity. Learn more. http://bit.ly/aM3TjP
Autologous Stem Cell Transplantation as a Care Opt... [Clin Lymphoma Myeloma Leuk. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on April 2, 2011 at 3:52 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Stem cell transplantation can be an option for patients with Waldenstrom macroglobulinemia (http://1.usa.gov/eGfmjS).
Hyperphosphorylated paratarg-7: a new molecularly ... [Blood. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on January 12, 2011 at 1:37 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Hyperphosphorylated paratarg-7 is a risk factor for IgM-MGUS and Waldenstrom's macroglobulinemia (http://bit.ly/igzFQ4).
Hematopoietic cell transplantation for Waldenström... [Bone Marrow Transplant. 2011] - PubMed result
t.co — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at t.co
Most Recently Shared on July 10, 2011 at 11:39 am By:
Robert Z. Orlowski Physician, Doctor, and Internist
Nice review: Stem cell transplantation in #Waldenstrom macroglobulinemia http://t.co/ZohZx1Z. Chemosensitive disease best prognostic factor.
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for... -- NEW YORK, Jan. 29 /PRNewswire-FirstCall/ --
prnewswire.com — “Keryx biopharmaceuticals announces positive phase 2 study results of perifosine as a single agent for the treatment of advanced waldenstrom's macroglobulinemia. data demonstrating a 35% overall response rate with a median progression-free survival of 12.6 months in patients with relapsed or relapsed/refractory” View full resource at prnewswire.com
Most Recently Shared on January 29, 2010 at 2:05 pm By:
Positive Results for study on new drug for #Waldenstrom's. http://bit.ly/b9Khug
Oncology Medical News about Everolimus
mdlinx.com — “Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia” View full resource at mdlinx.com
Most Recently Shared on February 16, 2010 at 3:14 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Oncology Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory W... http://bit.ly/9KkcPk
The Role of Serum Immunoglobulin Free Light Chain ... [Clin Cancer Res. 2011] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on March 19, 2011 at 12:43 pm By:
Robert Z. Orlowski Physician, Doctor, and Internist
Serum free light chains are useful markers of disease response and progression in Waldenstrom macroglobulinemia (http://1.usa.gov/i7qK1q).
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Lymphomation.org
Lymphomation.org/Patients Against Lymphoma -- Providing support and timely access to evidence-based information on lymphomas and their treatment.
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement
